Version history

{
  "session_id": "pan_f11f02fc",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "pantheon-stub",
  "action": "respond",
  "content": "\n\n## My Position: The Hypothesis Has Become Inverted—It's Time to Reframe the Cascade\n\nThe amyloid cascade hypothesis is not merely wrong; it's been **mis-specified at a level of granularity the original framing didn't anticipate**. The hypothesis predicted that removing amyloid would halt disease progression. It doesn't—not even close (PMID: 35704286). This isn't a refinement problem; it's a structural problem. The cascade metaphor assumes linear causality, but the data increasingly suggests amyloid is a **downstream convergence point** rather than the initiating lesion.\n\n### What Amyloid Actually Explains Well\n\n- Genetic early-onset AD (APP, PSEN1/2 mutations) remains squarely in amyloid territory\n- Amyloid PET positivity correlates with increased risk, not clinical disease\n- The 30-40% of cognitively normal elderly with amyloid plaques suggests it can exist as a \"necessary but insufficient\" finding (PMID: 30322784)\n\n### Why the Cascade Is Inverted\n\nThe defining failure isn't that anti-amyloid antibodies don't clear plaques—they often do. It's that clearing plaques doesn't meaningfully slow cognitive decline in most patients (PMID: 35819586). Lecanemab's 27% slowing over 18 months is real, but it's treatment of late-stage pathology, not upstream intervention.\n\nThe alternative framing that fits the data better: **proteostasis failure** is the upstream driver. Lysosomal dysfunction, mitochondrial compromise, and chronic microglial activation create conditions where amyloid becomes a collateral consequence—an aggregative response to cellular failure rather than its cause. Amyloid is the smoke; the fire is deeper.\n\n### My Distinctive Claim\n\nThe amyloid hypothesis should be reformulated from \"amyloid causes AD\" to \"AD involves multiple upstream stressors that converge on amyloid as one of several pathological outputs.\" This reframes therapeutic strategy: targeting amyloid remains reasonable as one arm of a multi-target intervention, but *monotherapy against amyloid* in sporadic, late-onset AD was always fighting downstream. The cascade runs the other direction for most patients.\n\n**Confidence: 0.75** — The genetic forms clearly support amyloid primacy in inherited disease; the reframing is stronger for the 95%+ of AD that is not early-onset familial.",
  "tokens_used": "0",
  "persona_id": "persona-theorist"
}